Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia

Figures & data

Table 1. Patient characteristics.

Characteristics	ATG group (%)	PTCy intensified group (%)	P-value
	Protocol (n = 18)	Protocol (n = 22)
Gender
Male	11 (61.1)	15 (68.2)	0.744
Female	7 (38.9)	7 (31.8)
Age
≤10 years	5 (27.8)	7 (31.8)	1.000
>10 years	13 (72.2)	15 (68.2)
Diagnosis
AML	5 (27.8)	10 (45.5)	0.332
ALL	13 (72.2)	12 (54.5)
Leukocyte count at diagnosis
<30 × 10^9/L	7 (63.9)	15 (68.2)	0.110
≥30 × 10^9/L	11 (63.9)	7 (31.8)
Disease status Pre-HSCT
CR1	5 (22.7)	3 (16.7)	0.084
≥CR2	15 (68.1)	13 (72.2)
NCR	2 (9.1)	2 (11.1)
MRD Pre-HSCT
Positive	2 (11.1)	6 (27.2)	0.258
Negative	16 (88.9)	16 (72.7)
Molecular aberrant
FLT3-ITD	2 (9.0)	1 (5.6)	0.579
MLL	1 (4.5)	2 (11.1)	1.000
WT1	1 (4.5)	0	0.450
RUX1	1 (4.5)	2 (11.1)	1.000
BCR-ABL	2 (9.0)	0	0.196
E2A	1 (4.5)	0	0.450

PTCy, post-transplantation cyclophosphamide; ATG, Anti-thymocyte globulin; MRD, minimal residual disease; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CR, complete remission.

Figure 1. Comparison of II–IV aGVHD and III–IV aGVHD in PTCy intensified group vs ATG group (P = 0.048 and 0.193, respectively).

Figure 2. Comparison of cGVHD and extensive cGVHD in PTCy intensified group vs ATG group (P = 0.318 and 0.440, respectively).

Figure 3. Comparison of two-year OS (a), LFS (b), GRFS (c), and RI (d) in PTCy intensified group vs ATG group.

Table 2. Infection complication.

Infection complication	ATG group (%)	PTCy intensified group (%)	P-value
Cytomegalovirus viremia	12 (66.7%)	16 (72.7%)	0.738
Epstein-Barr virus viremia	3 (16.7%)	4 (18.2%)	1.000
Pneumonia	2 (11.1%)	3 (13.6%)	1.000
Perianal infection	2 (11.1%)	4 (18.2%)	0.673
Septicemia	3 (16.7%)	2 (9.1%)	0.642

PTCy, post-transplantation cyclophosphamide; ATG, anti-thymocyte globulin.